Skip to main content
Premium Trial:

Request an Annual Quote

Millions of Mosquitoes

The final OK has been given to a plan to release more than 750 million genetically engineered mosquitoes in the Florida Keys, CNN reports.

The firm that developed the mosquitoes, Oxitec, has been seeking to test the mosquitoes, which aim to decrease the number of wild Aedes aegypti mosquitoes that can carry diseases like chikungunya, dengue, yellow fever, and Zika in Florida for years. It has previously tested them in Brazil, where it says their introductions led to a 90 percent drop in the number of wild mosquitoes. The engineered mosquitoes are male and carry a gene that, when they mate with wild female mosquitoes, causes the resulting larvae to die before reaching adulthood. 

CNN notes that the Florida Keys Mosquito Control District had reached out to Oxitec in 2012 to help control its Ae. aegypti population, but there was public outcry against trials. A 2016 non-binding public referendum in the county approved the trial, though the precinct where the trial was to occur voted against it. The firm further developed a new engineered mosquito, also male, that only kills female mosquitoes, CNN adds.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.